Foothill Ranch, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Global sweetness and flavor innovator Sweegen has announced that its Bestevia® Rebaudiosides M (Reb M), D, and E have received full authorization from the Taiwan FDA for use in food and beverages. This recent regulatory approval marks another milestone in Sweegen successfully opening new markets in countries where brands seek new generation stevia ingredients to expand their sugar reduction solutions.
Reb M, a high-purity steviol glycoside derived from the stevia plant, is renowned for its clean and sugar-like taste profile. The best-tasting part of the stevia leaf, such as Reb M is found in trace quantities of the leaf's composition.
For food and beverage producers, Sweegen’s Reb M technology offers several commercially significant advantages. Sweegen’s Signature Stevia starts with stevia, not GMO corn or sugar beets. The ingredient innovator leverages proprietary bioconversion technology to produce a range of zero-calorie sweeteners with assured quality, regulatory compliance, and competitive prices. These products generate a lower carbon footprint.
As Sweegen continues to excel in commercialization and secures essential regulatory approvals in key markets like the EMEA and the U.K., the company witnesses substantial sales growth throughout 2023.
In addition to those critical regulatory approvals, Sweegen now offers its food and beverage manufacturing customers the right to use its Reb M in all non-alcoholic beverages anywhere in the world without infringing the relevant application patents. Customers already use Sweegen’s Reb M in other applications.
"At Sweegen, our focus revolves around safety, quality, and adherence to regulatory standards,” said Vice President of Technical and Regulatory Affairs, Hadi Omrani. “We are expanding our global footprint by opening new markets to create access to innovative sweetener technologies.”
With increased interest from the global CPG companies and their desire for guaranteed capacity and supply chain redundancy, Sweegen has been working to establish and expand production facilities in major markets, including EMEA, North America, and APAC.
"The approval of Bestevia Reb M in Taiwan represents a breakthrough for brands aiming to create better-for-you foods and beverages,” said Vice President of Global Innovation, Casey McCormick. “Bestevia Reb M opens innovative avenues for reducing and even eliminating sugar, surpassing consumer expectations and contributing to public health goals aimed at curtailing sugar intake."
Sweegen has recently achieved FEMA GRAS status for its sweet proteins, brazzein and thaumatin II, which serve as valuable complements to steviol glycosides in the realm of food and beverage production. This addition reinforces Sweegen's commitment to broadening its portfolio of innovative taste-modulating flavors. These sweet proteins are pivotal in assisting food and beverage manufacturers in meeting the rising demand for better-for-you products, aligning seamlessly with consumers' holistic wellness preferences. The brazzein technology takes center stage in Sweegen's newly launched Sweetensify™ flavor technology for taste modulation. It is an ideal tool for brands aiming to replicate sugar-like tastes in their food and beverage offerings.
Sweegen is dedicated to revolutionizing the sweetener market with innovative solutions that promote healthier choices without compromising taste. The full authorization of Bestevia Reb M in Taiwan reinforces Sweegen's leadership in the nature-based sweetener space and positions the company as a trusted partner for food and beverage manufacturers worldwide.Top of FormBottom of Form
###
Sweegen provides sweet-taste solutions for food and beverage manufacturers around the world.
The company aims to reduce sugar and artificial sweeteners in the global diet. Partnering with customers, Sweegen creates delicious zero-sugar products that consumers love. With the best modern sweeteners in its portfolio, such as Bestevia® Rebs B, D, E, I, M, and N, and sweet proteins brazzein and thaumatin, along with its deep knowledge of flavor modulators and texturants, Sweegen delivers market-leading solutions that customers want, and consumers prefer. Well. Into the Future.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1996. Sweegen’s actual results may differ from the estimates, assumptions, and other illustrative material contained herein, and consequently, a reader should not rely on these forward-looking statements as predictions of future events. These forward-looking statements include, without limitation, illustrative information regarding Sweegen’s bottom-up assumed market potential, assumed hit rate, and the resulting revenue based on these model inputs. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
Industry, Market, and Other Data
In this press release, we rely on and refer to information and statistics regarding market participants in the sectors in which Sweegen competes and other data. We obtained this information and statistics from our own internal estimates and third-party sources, including reports by market research firms and company filings. We do not expressly refer to these sources. All of this information involves a number of assumptions and limitations, and the sources of such information cannot guarantee the accuracy or completeness of such information. The industry in which Sweegen operates is subject to a high degree of uncertainty and risk due to a variety of important factors, any of which could cause results to differ materially from those expressed in the estimates made by Sweegen or third parties.
Further Cautionary Statement Concerning Forward-Looking Statements
This press release contains forward-looking statements, including, among other statements, statements regarding the future prospects for Reb M stevia leaf sweetener, brazzein, and thaumatin. These statements are based on current expectations but are subject to certain risks and uncertainties, many of which are difficult to predict and beyond Sweegen's control.
Relevant risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements and, therefore, should be carefully considered. Sweegen assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.
Attachments
